The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 12, 2002
Filed:
Nov. 15, 1995
S. Christopher Bauer, New Haven, MO (US);
Mark Allen Abrams, St. Louis, MO (US);
Sarah Ruth Braford-Goldberg, St. Louis, MO (US);
Maire Helena Caparon, Chesterfield, MO (US);
Alan Michael Easton, Maryland Heights, MO (US);
Barbara Kure Klein, Town & Country, MO (US);
John Patrick McKearn, Glencoe, MO (US);
Peter Olins, Glencoe, MO (US);
Kumnan Paik, Ballwin, MO (US);
Joseph Polazzi, Chesterfield, MO (US);
John Warren Thomas, Town & Country, MO (US);
Pharmacia Corporation, St. Louis, MO (US);
Abstract
The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids (a.a.119 to 133) have been deleted from the C-terminus, and which also contain amino acid substitutions in the polypeptide. These hIL-3 multiple mutation polypeptides may have biological activities similar to or better than hIL-3 and, in some cases, may also have an improved side effect profile.